Amarantus BioScience Holdings, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.amarantus.com
A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Amarantus BioScience Holdings, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02439125
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center, Boca Raton, Boca Raton, Florida, United States
Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds
Phase 2
- Conditions
- Thermal InjuryDeep Partial-Thickness BurnFull-Thickness Burn
- Interventions
- Drug: Autologous Engineered Skin SubstituteDrug: Split-Thickness Autograft (AG)
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Amarantus BioScience Holdings, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01655407
- Locations
- 🇺🇸
US Army Institute of Surgical Research, Houston, Texas, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
🇺🇸Arizona Burn Center, Pheonix, Arizona, United States
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
Phase 2
Completed
- Conditions
- Cognitive ImpairmentSchizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Amarantus BioScience Holdings, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01266174
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Duke University School of Medicine, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath